Today: 7 February 2026
Subscribe
Browse Category

NYSE:AZN News 16 September 2025 - 1 February 2026

AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week

AstraZeneca shares closed in London at 135.48 pounds Friday, up 0.65%. The company moves its U.S. listing from Nasdaq to the NYSE on Monday, keeping the AZN ticker. AstraZeneca recently announced a $1.2 billion obesity drug deal with CSPC and pledged $15 billion investment in China by 2030. Investors await full-year results on Feb. 10.
1 February 2026
·····
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
··········
AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

London, January 24, 2026, 19:48 GMT — Markets have closed A U.S. appeals court on Friday revived a lawsuit accusing AstraZeneca and several major drug and medical-device companies of funneling millions in cash and medical supplies to fund terrorism in Iraq. The plaintiffs claim the firms made corrupt payments to Jaysh al‑Mahdi, a militia backed by Hezbollah, to win contracts from the Iraqi Health Ministry. They are seeking unspecified damages under the U.S. Anti‑Terrorism Act. (Reuters) The announcement came after the U.S. market closed, forcing traders to factor in the risk when trading resumes Monday. It also casts a sudden
24 January 2026
···
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates

New York, January 20, 2026, 11:21 EST — Regular session AstraZeneca PLC’s U.S.-listed shares fell Tuesday after the company revealed plans to pull its American depositary shares from Nasdaq and directly list ordinary shares on the New York Stock Exchange. The stock slid 4.4%, dropping to $90.23 in late morning trading. The switch swaps depositary-share wrappers for ordinary shares in U.S. trading. Mostly a technical tweak, it can still shake up flows as brokers, index trackers, and arbitrage desks adjust positions before the change. AstraZeneca revealed in a U.S. regulatory filing that it will voluntarily delist its American depositary shares
20 January 2026
·····
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

New York, Jan 12, 2026, 07:52 EST — Premarket Tempus AI shares climbed roughly 12%, reaching $74.34 in Monday’s premarket session. (Investing.com) The bid emerged amid a volatile morning for growth stocks, with Nasdaq 100 futures slipping close to 1% as investors digested fresh doubts over the Federal Reserve’s independence and prepared for earnings season to begin. (Reuters) Tempus projected full-year 2025 revenue around $1.27 billion in an SEC filing, marking an 83% jump from the previous year. That includes roughly 30% organic growth without Ambry. Diagnostics revenue hit about $955 million, soaring 111%, while data and applications brought in
12 January 2026
··········
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

New York, Jan 12, 2026, 05:29 EST — Premarket Tempus AI, Inc. shares were up about 11% in premarket trading on Monday after the company flagged strong preliminary 2025 results and reported record contract value with drugmakers. Tempus AI traded at $73.66 in premarket action, after ending Friday at $66.27. (google.com) The update lands as investors head into the annual J.P. Morgan Healthcare Conference week, when companies often try to reset expectations and pitch their 2026 story. Tempus has been a high-beta name in that mix, moving sharply on growth signals. For Tempus, the market focus has narrowed to two
12 January 2026
········
MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

LONDON, Dec. 7, 2025 — The MSCI Europe Index slipped modestly at the end of the week but remains one of 2025’s equity standouts, still ahead of broad global benchmarks such as the MSCI World and MSCI ACWI. European stocks are pausing after a powerful rally, even as fresh forecasts from major banks signal further upside into 2026 and technical indicators continue to lean constructive. MSCI Europe Index: Latest Performance Snapshot At Friday’s close on 5 December 2025, the MSCI Europe Index (MIEU00000PUS) finished at 2,564.76, down 0.25% on the day after three sessions of gains. Investing.com Despite that small
7 December 2025
·············
Salesforce Stock Pops as Q3 2026 Earnings, AI Deals and AstraZeneca Partnership Lift Guidance — But Investor AI Skepticism Lingers

Salesforce Stock Pops as Q3 2026 Earnings, AI Deals and AstraZeneca Partnership Lift Guidance — But Investor AI Skepticism Lingers

Salesforce (NYSE: CRM) has triggered a fresh wave of headlines after posting record third‑quarter fiscal 2026 results, raising its full‑year outlook and signing a high‑profile AI deal with AstraZeneca. Yet despite the post‑earnings stock pop and new enterprise wins, CEO Marc Benioff is still fighting to convince Wall Street that Salesforce’s aggressive artificial intelligence strategy will translate into lasting shareholder returns. Salesforce Investor Relations+2Reuters+2 Q3 2026 by the numbers: record revenue, fatter margins For its fiscal third quarter ended October 31, 2025, Salesforce reported: On the bottom line, Salesforce delivered adjusted EPS of $3.25, handily beating the roughly $2.86 Wall
5 December 2025
·····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax SA (NASDAQ: ABVX), the French biotech behind the inflammatory bowel disease drug candidate obefazimod, is back on traders’ screens today as the stock spikes on fresh takeover chatter involving pharma giant AstraZeneca. As of mid‑afternoon U.S. trading on Thursday, November 20, 2025, ABVX stock is trading around $121.94, up roughly 8% from Wednesday’s close of $112.95. Intraday, shares have ranged between about $113.63 and $126.42, on heavy volume of roughly 3.7 million American Depositary Shares (ADSs). Stock Invest That move adds to what has already been one of the biggest biotech runs of 2025. Abivax is up more than
20 November 2025
·····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Richmond’s New Pharma Giant: Overview of Lilly’s $5B Factory Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost. Scale and Scope: The plant will
16 September 2025
·······

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop